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The growing fetus is dependent on adequate placental function for delivery of essential
nutrients and oxygen, and for waste removal. The placenta also plays an important
protective role; shielding the developing baby from the maternal immune system and
adverse environmental exposures. Fundamental to these processes is correct invasion
of the decidua and remodeling of maternal vasculature, each of which show remarkable
parallels to tumorogenesis, with the obvious exception that the former is usually a tightly
controlled process. It is not surprising that these physiological similarities are mirrored in
gene expression and epigenetic parallels, many not found in any other aspect of human
development. In this perspective, we summarize known DNA methylation similarities
between placenta and human tumors, and discuss the implications and knowledge gaps
associated with these ﬁndings.We also speculate on the potential origin of common DNA
methylation features in these two disparate aspects of human physiology.
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MOLECULAR PATHWAYS SHARED BY PLACENTA AND
CANCERS
Two of the most signiﬁcant physiological similarities between the
human placenta and cancer are invasion of surrounding tissue and
evasion of the host immune response. In the placenta these tasks
are primarily performed by the three distinct trophoblast popu-
lations; the stem-cell like villous cytotrophoblasts (VCT), invasive
extravillous trophoblasts (EVT), and the syncytiotrophoblast (ST)
layer. Invasion of decidua and remodeling of maternal vascula-
ture is carried out by EVTs, enabling the supply of blood to the
developing fetus via the placenta. Early in vitro studies of EVTs
conﬁrmed their invasive capacity (Yagel et al., 1988), with subse-
quent work showing the utility of transformed EVT cell lines as
models for tumor progression (Lala et al., 2002). This work also
highlighted the role of TGF-beta signaling via Smad3, and TIMP1
in the restriction of EVT invasion (Lala et al., 2002). Many other
genes are implicated in the invasive properties of EVTs, several
of which are also involved in tumor progression (reviewed exten-
sively in Soundararajan and Rao, 2004; Pollheimer and Knoﬂer,
2005; Ferretti et al., 2007).
Modulation of the maternal immune system is a major chal-
lenge for the developing pregnancy, a process that again displays
features usually only seen in cancer (Mullen, 1998). Immune
evasion is a multifaceted process that involves human chori-
onic gonadotrophin production by the ST layer, a lack of major
histocompatibility complex class I and II antigen expression, selec-
tive expression of HLA-G, and evasion of TGF-beta (reviewed in
Mullen, 1998; Holtan et al., 2009).
Other unique similarities between the placenta and cancer
include expression of human telomerase (hTERT; Nishi et al.,
2004), and placenta proteins (PPs) including SP1 (Inaba et al.,
1980), PLAC1 (Devor and Leslie, 2013), and CGB/LHB [in breast
cancer (Giovangrandi et al., 2001)]. Furthermore, a recent study of
a panel of 293 lung tumors linked the expression of testis/placenta
speciﬁc transcripts to lung cancer metastasis potential (Rousseaux
et al., 2013). The expression similarities also include micro RNAs,
with the 100 kb miRNA cluster, C19MC, exclusively expressed in
human placenta and cancers in association with hypomethylation
of an upstream CpG island (Bortolin-Cavaille et al., 2009; Tsai
et al., 2009).
GLOBAL HYPOMETHYLATION AND PARTIALLY METHYLATED
DOMAINS ARE A HALLMARK OF CANCER AND THE
PLACENTA
The earliest evidence for tumor-like methylome in the human
placenta came from a study in 1983. Gama-Sosa et al. (1983)
showed that the placental global methylation level (total % of
5-methylcytosine or 5meC) was approximately 3%, more similar
to human tumors (2.5–3.5%) than disease-free somatic tissues
(4–5%). Whereas a general increase in methylation occurs in
most somatic cells in association with differentiation, this process
appears attenuated in the extraembyronic lineage (Chapman et al.,
1984), manifesting as a reduced level of methylation at speciﬁc
repetitive DNA elements that comprises the bulk of mammalian
genomic DNA (Tabano et al., 2010).
More recently, a substantial proportion of the placental genome
(∼37%) has been shown to comprise stretches (>100 kb) of low to
intermediate methylation, generally highly methylated in somatic
tissues. Such partially methylated domains (PMDs) have only pre-
viously been reported in some cancers and cell lines (e.g., IMR90
and SH-5Y5Y cells) (Lister et al., 2009; Schroeder et al., 2013).
PMDs are associated with gene repression, and there is evidence
that CpG Islands within PMDs are hypermethylated compared to
CpG Islands within adjacent highly methylated domains (HMDs;
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Lister et al., 2009). The identiﬁcation of PMDs in the placenta sug-
gests that global hypomethylation in this tissue is not restricted to
repetitive elements. Currently there is very little known about the
establishment of PMDs and whether these regions are present in
other cell types, although it is clear thatmany genes involved in pla-
centa development and function (e.g., defense response) are found
in placenta-speciﬁc HMDs (Schroeder et al., 2013). This is in line
with a general higher expression of genes withinHMDs, compared
to PMDs, in the human placenta. The current view of PMDs in
cancer is that they contribute signiﬁcantly to the tumor speciﬁc
hypomethylation. Further study of PMDs in placenta and cancer
will providemore clues about the establishment,maintenance and
function of global DNAmethylation in placental development and
disease.
At present it is unclear whether tumor-associated global
hypomethylation is reﬂective of a reduced level of methylation
in cancer precursor cells, or whether this is the result of a
loss of methylation (either active or passive) as part of cancer
progression. It is worth noting that even premalignant benign
neoplasms are associated with a global decrease in DNA methy-
lation (Goelz et al., 1985). The role of DNA methyltransferases in
the genomic hypomethylation that is feature of cancer and the pla-
centa remains unclear, as does the impact of this hypomethylation
on genomic stability in the placenta; a hallmark of cancer-
associated hypomethylation. We previously identiﬁed DNMT1
(maintenance methyltransferase) promoter methylation in pri-
mate placenta (Novakovic et al., 2010), with subsequent studies
demonstrating that DNMT1 is imprinted speciﬁcally in placental
tissue (Yuen et al., 2011; Das et al., 2013). However, the DNMT1
promoter is not methylated in mouse placenta, suggesting it
is not essential for global hypomethylation. A recent study in
mice, showed that in vitro differentiation of ES cells to tro-
phoblast results in downregulation of Dnmt3a2 and upregulation
of Dnmt3a1 de novo methyltransferases, with no change in Dnmt1
and Dnmt3b expression. Interestingly, Dnmt1 was shown not to
localize to replication foci during S phase in this system in asso-
ciation with decreased expression of the Dnmt1 chaperone Np95
(Oda et al., 2013). It will be interesting to directly compare the
temporal expression patterns of genes involved in DNA methyla-
tion/demethylation in both human extra-embryonic lineage and
early malignancy.
EPIGENETIC ACTIVATION OF RETROVIRAL PROMOTERS AND
ENHANCERS
Transposable elements (TEs), including retrotransposons, com-
prise around half of the human genome. Some have demonstrated
roles in gene regulation (Emera andWagner, 2012). TEs can act as
promoters, enhancers or insulators, and are believed to have con-
tributed to the evolution of the placenta through the up-regulation
of speciﬁc gene pathways, such as cAMP signaling, in placenta and
endometrium (Lynch et al., 2011). Recent data have also identiﬁed
a broader role for tissue-speciﬁc retroelement hypomethylation in
association with enhancer activity (Xie et al., 2013) in humans.
Expression of genes through retrotransposon-derived pro-
moters is uncommon in somatic human tissue, due to epige-
netic silencing of these sequences (Emera and Wagner, 2012).
However, in the placenta these elements drive the expression
of several genes, including interleukin-2 receptor beta (IL2RB;
Cohen et al., 2011). Furthermore, these elements can act as
alternative promoters, giving rise to placenta-speciﬁc transcripts
in genes such as KCNH5, INSL4, EDNRB, PTN, and MID1
(Macaulay et al., 2011). In addition to activating existing genes,
some previously “parasitic” elements such as Human Endoge-
nous Retrovirus-encoded envelope proteins, Syncytin-1 and
-2, EnvP(b), and EnvV, have become “domesticated” to per-
form essential functions in placentation (Gimenez et al., 2009;
Vargas et al., 2009, 2012).
A recent transcriptome analysis of two placental and one non-
placental mammal discovered that 40% of the placental-speciﬁc
transposon family, MER20 were in the proximity (<200 kb) of
genes with endometrium-speciﬁc expression in placental mam-
mals (Lynch et al., 2011). This analysis suggests that MER20
acquisition by placental mammals played a major role in the evo-
lution of the placenta. Placenta-speciﬁc retrotransposon-derived
promoters can also be active in certain cancers in association with
DNA hypomethylation. For example, the expression of INSL4,
a candidate oncogene, is upregulated by hypomethylation of an
LTR-derived promoter in placenta (Bieche et al., 2003) and thy-
roid and breast cancer (Brandt et al., 2005; Rodriguez-Rodero
et al., 2013). Other placenta and cancer speciﬁc LTR promoter
driven genes include envelope proteins, such as ERVWE1, which
is hypomethylated in testicular cancer but not matched somatic
tissue (Gimenez et al., 2010). At present, it remains unclear
whether the global DNA hypomethylation seen in cancer results
in a similar increase in the number of active retrotransposon
promoters and enhancers elements (and associated changes in
gene expression proﬁle) as seen in the placenta. Further, it
remains unclear why placental retrotransposon hypomethyla-
tion does not appear to be associated with active transposition
of such elements in the genome, although few have investi-
gated this in any detail. Finally, it is intriguing to speculate
that placenta-speciﬁc epigenetic proﬁles of the different para-
sitic DNAs present in different species may play a role in the
well documented differences in placental structure and func-
tion that are widespread in eutherians. This is supported by
studies in the rat and mouse placenta that have identiﬁed epi-
genetic activation of rodent-speciﬁc endogenous retroviruses as a
major driver of placental speciﬁc enhancer activity (Chuong et al.,
2013).
PLACENTA-SPECIFIC TUMOR SUPPRESSOR METHYLATION–
A HIDDEN PATHWAY TO CANCER DEVELOPMENT?
Wide-spread DNAmethylation-mediated silencing of tumor sup-
pressor genes (TSGs) is a hallmark of human cancer (Timp and
Feinberg, 2013). In the placenta, the search for speciﬁc DNA
methylation biomarkers with utility for non-invasive diagnosis
of pregnancy-associated disease, led to the discovery of placenta-
speciﬁc hypermethylation of the RASSF1A TSG (Chan et al., 2006;
Chiu et al., 2007). RASSF1A is involved in a variety of cellular
pathways, and is the most commonly silenced TSG in human
cancers (Agathanggelou et al., 2005) and the demonstration of
placenta-speciﬁc methylation was the ﬁrst identiﬁcation of TSG
silencing through hypermethylation in any non-cancerous tissue.
This was closely followed by the report of Maspin silencing in
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ﬁrst trimester placenta through histone repression (Dokras et al.,
2006). Our group, and others, subsequently identiﬁed several
TSGs with a placenta-speciﬁc methylation proﬁle, most notably
multiple negative regulators of canonical Wnt/ β-catenin signal-
ing, including APC, SFRP2, WIF1, and EN1 (Novakovic et al.,
2008; Wong et al., 2008; Guilleret et al., 2009). This pathway plays
a key role in cell migration and invasion associated with embryo-
genesis and tissue development via β-catenin regulation of gene
expression (Polakis, 2012). There is now clear evidence for a
role of Wnt signaling in placental function, speciﬁcally the dif-
ferentiation of cytotrophoblasts to extravillous cytotrophoblasts
(reviewed in Knoﬂer and Pollheimer, 2013). Deregulation of
this pathway is a key feature of many different cancers (Clevers,
2006), including placental related tumors and hydatidiform mole
(Pollheimer et al., 2006).
There is a complex interplay between inhibition and promo-
tion of Wnt signaling in the placenta which may play a role in
controlled invasiveness. For example, the promoter of WNT2
(ongogenic in cancer; Vider et al., 1996) shows placenta-speciﬁc
hypermethylation (Yuen et al., 2009). In addition, the placenta
shows an intermediate level of methylation at TSG promoters,
as opposed to the complete hypermethylation observed in can-
cer. However, recent epigenomic analysis in cancers of different
origins, suggests that most CpG Island hypermethylation events
in cancer occurs at genes that are already silenced in the healthy
tissue of origin (Sproul et al., 2012). Therefore, the majority of
hypermethylation eventsmay occur following cancer development
and progression, and are therefore “passenger”methylation events
(Sproul and Meehan, 2013; Timp and Feinberg, 2013). Neverthe-
less, there is evidence for a role of DNA methylation-mediated
silencing in cancer progression and survival (De Carvalho et al.,
2012). Whether the monoallelic methylation of TSGs in the
human placenta plays a driving role in function and develop-
ment is not certain, although the accumulation of β-catenin
during trophoblast differentiation suggests that methylation of
negative regulators of Wnt signaling has some functional role
(Knoﬂer and Pollheimer, 2013).
Unlike cancers, which have different origins, and there-
fore different “default” gene expression and methylation marks,
methylation of TSGs in placenta appears to be an orchestrated
developmental process, and in several cases may involve genomic
imprinting (Guilleret et al., 2009). It would be very informative
to pinpoint the exact time during development that these methy-
lation marks are established, and if this results in an expression
change. For example, are the marks present in the trophectoderm
at the blastocyst stage? Unfortunately, it is not possible to measure
methylation in primary human trophectoderm, and iPS cells have
yet to be differentiated into trophectoderm. Therefore, we are lim-
ited to cells fromtheﬁrst trimester of pregnancy (∼8weeks),which
already show mono-allelic methylation of TSGs. Furthermore,
mouse studies are not useful, because the majority of the monoal-
lelic methylation of TSGs observed in humans is not present in
mice. However, trophoblastic choriocarcinoma cell lines give us
some insights into the role of TSG methylation in placenta. In
these cell lines, TSGs that show mono-allelic methylation in nor-
mal placenta are completely hypermethylated (Novakovic et al.,
2008). This highlights the pre-malignant nature of normal human
placentation, in that the TSG methylation is developmentally
established to the extent that it facilitates normal development,
but prevents overt invasion of trophoblasts. Therefore, the pla-
centa displays a limited proﬁle of TSG methylation, which may
play a key role in controlling the “pseudomalignant” nature of
placentation.
CANCER ASSOCIATED DNA METHYLATION AND
TROPHOBLAST FUNCTION
The coordinated, placenta-speciﬁc methylation of several TSGs
constitutes prima facie evidence for a role of DNA methylation
in regulating trophoblast function. However, in many instances
this has not yet been directly demonstrated, primarily due to
the lack of suitable model systems. Commonly used cell lines are
often derived from placental malignancies whereas non-primates
placentae lack much of the observed TSG methylation seen in
primates (Ng et al., 2010). The most informative data will likely
come from studies in isolated primary trophoblasts. One such
study has linked higher methylation at two TSGs, MMP2, and
PRKCDBP, with trophoblast invasion (van Dijk et al., 2012). A
systematic and expanded analysis of this kind has the poten-
tial to identify many epigenetically regulated genes with essential
roles in trophoblast function. An alternative approach is to link
observational studies in humans to functional analysis in cell
lines. For example, Shi et al. (2012) identiﬁed high MASPIN
expression in a cohort of women with preeclampsia, and using
5-aza treatment (a DNA methylation inhibitor) showed that
MASPIN demethylation, and elevated expression, decreased pro-
liferation and migration in the TEV1 trophoblastic model cell
line.
LOSS OF IMPRINTING IN HUMAN PLACENTA
Loss of imprinting (LOI) refers to the gain of expression from
the usually silenced allele of an imprinted gene (Lambertini et al.,
2008b). LOI is one of the earliest and most common epigenetic
aberrations in cancers (Jelinic and Shaw, 2007). A number of stud-
ies have demonstrated that LOI occurs frequently in human term
placenta, with much higher rates in the ﬁrst trimester (Lambertini
et al., 2008a; Diplas et al., 2009b). The authors argued that LOI in
the ﬁrst trimester might be a regulatory mechanism promoting
trophoblast invasion and the establishment of placentation. Fur-
thermore, the lack of correlation between LOI and gene expression
level, and the all-or-nothing pattern of LOI at the single cell level in
cytotrophoblasts, suggest that LOI plays a role in placental devel-
opment by introducing variation in cell phenotype (Diplas et al.,
2009a; Pozharny et al., 2010).
It is possible that frequent LOI in human placenta is due
to DNA-methylation-mediated silencing of DNMT1 (possibly
maternally imprinted) in primate placenta (Yuen et al., 2011;
Das et al., 2013). Potentially, DNMT1 imprinting may result in
less strict maintenance of mono-allelic methylation at several
imprinted genes. A case for a role of DNMT1 in controlling DNA
methylation at imprinted genes comes from the observation that
DNMT1 is completely hypomethylated in trophoblastic chori-
carcinoma cell lines, while TSGs with monoallelic methylation
in normal placenta are completely hypermethylated in these cell
lines (Novakovic et al., 2008). Furthermore, LOI is not common
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in the mouse placenta, which potentially also has more genes
under imprinting control. This has led to suggestions that genomic
imprinting is more important in mice compared to humans, due
to lack of intra-uterine competition in the latter (Monk et al.,
2006). Interestingly, the mouse placenta is less invasive, with little
similarity to an invasive tumor, and the Dnmt1 promoter is not
methylated (Ng et al., 2010). It would therefore be interesting to
test if LOI is common inbaboon andmarmoset placenta,which are
also more invasive, and in which the DNMT1 promoter is mono-
allelically methylated (Novakovic et al., 2010). A ﬁnal note on the
role of methylation-mediated DNMT1 imprinting would be that
in our previous comparative analysis, we did not identify an associ-
ation between DNMT1 methylation and global hypomethylation
in the placenta. Indeed, both primates and non-primate placen-
tas showed hypomethylation, regardless of DNMT1 promoter
methylation level (Novakovic et al., 2010). Therefore, the poten-
tial role for DNMT1 imprinting in the frequent LOI or any other
epigenetic phenomenon in the placenta needs to be investigated
further.
A COMMON ORIGIN OF DNA METHYLATION FEATURES IN
THE PLACENTA AND CANCER?
Identiﬁed epigenetic similarities conserved in placentation and
cancer span a broad range of processes and cellular pathways,
from an overall global hypomethylation of genomic DNA, con-
served across species, to a speciﬁc proﬁle of Tumor Suppressor
gene methylation, largely restricted to primates (Table 1). Such
coordinated epigenetic features may simply reﬂect the indepen-
dent use of the same similar pathways for cell invasion, immune
modulation and vascular remodeling associated with the rapid
evolution of this tissue across mammals. More intriguingly, the
higher incidence of cancer in placental mammals relative to other
lineages raises the possibility that cancer may involve inappro-
priate “reactivation” of molecular pathways usually restricted to
placental development. Either way, it is now clear that studying
epigenetics in the placenta offers a unique opportunity to under-
stand the processes leading to aberrant epigenetic change associate
with human cancer. However, this will not be easy given the pre-
viously described lack of conservation of many epigenetic features
Table 1 | Key epigenetic similarities between the placenta and human cancer.
Feature Detail
Global hypomethylation Placental tissue and human cancers show a global 5-methylcytosine
content of ∼3%, lower than that of all disease-free somatic tissues
(4–5%). This is associated with a loss of methylation at speciﬁc repeat
sequences (mainly LINE1) that comprise the bulk (∼50%) of genomic
DNA and long genomic regions of intermediate methylation, called
partially methylated domains (PMDs), which cover 37% of the placental
genome. The presence of PMDs is a feature of most human cancers.
Gama-Sosa et al. (1983), Tabano et al.
(2010), and Schroeder et al. (2013)
Tumor suppressor gene (TSG)
methylation
RASSF1A is hypermethylated in almost every cancer type and was the
ﬁrst TSG shown to be speciﬁcally methylated in the placenta.
Methylation of multiple negative regulators ofWnt signaling (APC,
WIF-1, SFRP2, EN1) demonstrates coordinated epigenetic regulation of
signaling pathways in placenta and cancer. Multiple examples of
monoallelic methylation indicate a potential suite of novel imprinted
genes involved in the regulation of placentation in humans.
Chiu et al. (2007), Novakovic et al. (2008),
Wong et al. (2008), and Guilleret et al.
(2009)
Loss of imprinting (LOI) Imprinting (parent of origin allele speciﬁc expression) is regulated by
DNA methylation. LOI common in placenta, and is one of the most
consistent epigenetic aberrations observed in cancer.
Lambertini et al. (2008a) and Diplas et al.
(2009b)
Cryptic promoter/enhancer
activation
Global hypomethylation results in placenta-speciﬁc activation of
transposable elements to produce novel promoter and enhancer
elements. This leads to generation of placenta-speciﬁc transcripts of
endogenous genes. Additionally, several retrotransposable elements are
exclusively expressed in the placenta and cancer and are essential for
faithful placentation.
Macaulay et al. (2011) and Vargas et al.
(2012)
miRNAs Some miRNA genes, including the large microRNA cluster C19MC, are
expressed only in the placenta and in human cancers in association with
hypomethylation of an upstream CpG islands. Altered miRNA
expression leads to placental/cancer speciﬁc changes in downstream
gene expression of target loci.
Bortolin-Cavaille et al. (2009)
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of primate placentas, and the clear temporal changes in cell com-
position and epigenetic status in human placentation throughout
pregnancy. Further, the placenta is a complex tissue made up of
multiple cell types each with a speciﬁc function. Each needs to
be examined as puriﬁed populations, preferably over the length
of gestation. Only then will it be possible to link speciﬁc tumor-
like epigenetic marks to speciﬁc placental cell subtypes and cell
functions.
A ROADMAP FOR FUTURE EPIGENETIC STUDIES IN THE
PLACENTA
The majority of studies aimed at identifying gene expression or
epigenetic aberrations associated with pregnancy outcome or later
health have been done on whole placental biopsies collected at
delivery. This is inappropriate for two reasons: ﬁrstly, the pla-
centa is a complex tissue made up of numerous cell types, each
known to show gene expression and epigenetic differences. Anal-
ysis of whole tissue is likely to mask molecular features conﬁned
to speciﬁc cell types, which is also a problem in cancer studies, as
cancer biopsies contain several different cell types. Further, the full
term placenta is morphologically and functionally distinct from
the early pregnancy placenta, a likely critical time point for the
development of pregnancy-associated problems. Thus an analysis
of ﬁrst trimester samples (obtainable from elective termination or
as part of chorionic villi sampling (CVS) is essential, as is puriﬁ-
cation of the multiple different cell types that comprise this tissue.
Such an approach will most likely require reﬁnement of current
methodologies for cell isolation from placental biopsies and the
identiﬁcation of additional cell type-speciﬁc cell surface markers
for cell sorting. CVS collection also provides a unique opportunity
to perform functional studies on ﬁrst trimester placental cells in
culture (Campbell et al., 2007) although it is clear that the tro-
phoblast compartment is not the predominant cell population in
CVS cultured tissue. The integration of in vitro studies, epigenetic
proﬁling and pregnancy outcome at term, will provide important
links between placental function and outcome. Another impor-
tant area of future study will be the elucidation of mechanism
behindDNAmethylation and demethylation during trophoblastic
differentiation and development. State-of-the-art-technological
advances can now be used to measure several different forms of
methylated cytosine, including 5-hydroxymethylation (5hmC), 5-
formylcytosine (5fC), and 5-carboxylcytosine (5caC). Generally
present at lower levels than 5MeC, these forms of methylated cyto-
sine are likely intermediates in a demethylation process, but may
also have speciﬁc functional roles in gene expression regulation.
Proﬁling such modiﬁcations in the placental may therefore pro-
vide valuable insight into speciﬁc aspects of placental function
and/or spatial and temporal control of DNA methylation mainte-
nance and removal in the human placenta. It will be especially
interesting to determine the role of these modiﬁcations dur-
ing the differentiation process from stem cell like VCTs to EVTs
and the ST layer. Speciﬁcally, whether some genes are subject
to active demethylation during this process. Finally, it is likely
that many of the differences seen in mammalian placentas (the
most rapidly evolving tissue/organ in mammals) are speciﬁed, at
least in part, epigenetically. Therefore, comparing epigenetic pro-
ﬁle across species represents a valuable approach for identifying
epigenetic features underlying key processes speciﬁc to primate
placentation.
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